Tuesday, August 25, 2009

Are Boehringer cutting 600 US rep jobs?

That's what Insider hears. Thirty percent - gone!

Apparently horrible trial results for currently promoted drugs combined with Mirapex going off patent and losing Flomax to generic as well has led to a cut of 600 or more reps in the USA.

Notifications were on Tuesday morning via a phone call to impacted reps.

8 comments:

Anonymous said...

Its a massacre at BI. Huge cuts!

Anonymous said...

While the CEOs of this company collect bonus checks to well exceed what they are paid in salary. This system in America is wrong.......the people at the top or board of directors take from the cookie jar. They are even guaranteed payments if the company doesn't make a profit.
The Sales rep for these companies have always been a grunt for these people.

Anonymous said...

DMs are on the chopping block today, RDs tommorrow. Same thing - by phone.

Anonymous said...

actually closer to 1800 laid off

Anonymous said...

Is it just sales?

Anonymous said...

Anything to do with the poor results so-far for Dabigitran?

Anonymous said...

Numerous internal positions will be moved to the Germany headquarters. Internal people will find out soon enough.

BI sales will be highly dependent on the new "Clinical Science Consultants," whom are medically degree people (MD, PharmD, PA, RN, etc.), based upon the thought that practicing physicians will prescribe more because of the degree association.
Wrong move.

Anonymous said...

"Clinical Science Consultants" is just a fancy term for off-label promotion. I know. I used to be one.